Insights/How Modern Telehealth Platforms Build Revenue at Scale
BlogFUSE Health · 7 min read

How Modern Telehealth Platforms Build Revenue at Scale

How Modern Telehealth Platforms Earn Revenue
TLDR

The telemedicine market reached $114.98 billion in 2023 and is projected to grow at a 17.96% CAGR through 2030.[1] Telehealth is not a single business model — it is a category with radically different approaches to revenue, delivery, and scale. Understanding which model fits your goals is the difference between a sustainable platform and an expensive compliance project. ⚠ Disclaimer: This article is for informational purposes only. It does not constitute medical, legal, or financial advice. Consult qualified professionals before launching any health program or business.

The Five Core Telehealth Business Models

Every telehealth business ultimately falls into one of five revenue architectures. Knowing which one you are building before you spend on infrastructure, saves months and capital.

Direct-to-Consumer Subscription: Patients pay a monthly or quarterly fee for ongoing access to clinical review, prescriptions, and medication delivery. This is the dominant structure in prescription wellness, weight management, hormone therapy, peptide programs. Revenue is predictable, LTV is compoundable, and acquisition cost amortizes across many billing cycles rather than a single transaction.

Pay-Per-Consultation: Patients pay per individual visit with no recurring commitment. Works for acute care or episodic conditions but produces volatile revenue. Each patient requires a fresh acquisition trigger for every billing event, making CAC economics difficult to sustain without high visit frequency.

Employer and B2B: Telehealth access is bundled into employee benefits packages or sold to enterprise wellness programs. Contracts deliver stable revenue but involve longer sales cycles, volume commitments, and institutional procurement processes. Better suited to operators with existing enterprise relationships than to brand-first DTC operators.

Insurance Integrated: Providers bill insurance payers for reimbursable telehealth visits. Requires provider credentialing, billing infrastructure, payer contracting, and claims processing overhead. High per-visit revenue but significant administrative load — unsuitable for most non-clinical operators entering telehealth from a brand or wellness angle.

White Label Platform as a Service: Non-clinical operators license a turnkey clinical infrastructure stack licensed providers, pharmacy integrations, HIPAA compliance, and prescribing workflows and operate it under their own brand. The operator contributes audience trust and acquisition. The platform provides everything clinical. This is the fastest and lowest-capital-requirement path for brand operators entering prescription wellness.

Why the DTC Subscription Model Dominates

The real innovation of DTC telehealth platforms like Hims and Hers is not telemedicine — it is the conversion of episodic clinical needs into a subscription revenue stream. That architectural decision produces three compounding economic advantages that pay-per-visit models structurally cannot replicate.

Predictable cash flow. Monthly recurring revenue from an active subscriber base smooths the revenue volatility that destroys DTC health businesses relying on seasonal or impulse purchase patterns. Forecasting, staffing, and capital allocation all improve with MRR visibility.

Lower patient acquisition cost amortization. A $100 CAC against a $99/month subscription with 10-month average retention produces $990 in gross revenue per patient acquired an LTV:CAC ratio of nearly 10:1. The same $100 CAC against a single $99 visit produces a ratio of approximately 1:1. The subscription changes the entire acquisition math.

Clinical relationship continuity. Patients enrolled in ongoing programs weight management, hormone optimization achieve better outcomes than those in episodic care precisely because the clinical relationship persists. Better outcomes reduce voluntary churn. Reduced churn compounds LTV further. The clinical and business incentives align.

Hims & Hers reported over 2 million subscribers in their most recent annual report, with subscriber LTV driving the majority of their recognized revenue.[2] The subscription model is not a trend. It is the architecture that makes DTC telehealth defensible.

The Unit Economics of a Telehealth Business

A telehealth business at 1,000 active patients paying $150/month generates $150,000 in gross monthly revenue. Whether that revenue produces a profitable business depends entirely on the cost structure underneath it.

In a manually operated clinic model, the cost components compound quickly: licensed provider payroll or 1099 costs (typically $60–$90/hour for NPs), malpractice insurance ($5,000–$20,000/year per provider), pharmacy coordination labor, HIPAA compliance infrastructure, credentialing overhead, and customer support. These costs carry as fixed or semi-fixed charges regardless of patient volume fluctuations meaning a bad acquisition month still produces full cost exposure.

In a white label platform model, these layers shift from fixed costs the operator builds to variable costs embedded in the platform fee structure. The operator pays a percentage of revenue or a per-patient fee. When volume drops, platform costs drop proportionally. When volume grows, clinical infrastructure scales automatically without operator-managed hiring.

The practical result: white label operators typically reach contribution margin positivity at lower patient volumes than clinic-build operators, because the breakeven threshold is not anchored to a fixed clinical overhead base.

For operators modeling this decision, the calculation requires mapping: cost per patient acquisition, expected monthly subscription value, estimated average retention (months), and platform cost per active patient. The economics favor platform models most strongly in the 100–5,000 active patient range before custom infrastructure investment begins to amortize

How White Label Telehealth Changes the Economics

White label telehealth platforms restructure the P&L of a clinical operator in ways that a clinic-build model cannot match at early stage.

The licensed providers, pharmacy integrations, HIPAA-compliant workflows, and prescribing infrastructure are provided by the platform as part of its operating model. The operator earns margin on patient program revenue without carrying the clinical cost structure underneath it.

This does not mean white label is always the right model for every operator. Operators with unique clinical differentiation, existing provider networks, or technical requirements no platform covers may find custom infrastructure worthwhile over a longer time horizon. But for brand-first operators wellness brands, med spas, fitness platforms, e-commerce businesses entering telehealth for the first time, the white label model typically produces:

  • Revenue start within weeks rather than 12–18 months
  • Compliance infrastructure from day one rather than built in parallel to operations
  • Clinical overhead that scales with revenue rather than against it
  • No provider credentialing, malpractice management, or pharmacy contract negotiation

FUSE Health is built specifically for this operator category providing the complete clinical stack as infrastructure that non-clinical brands configure and deploy under their own brand.

Which Telehealth Business Model Is Right for You

The right model depends on what you bring into the market and what your revenue timeline requires.

If you are a licensed clinical operator with existing patients, provider relationships, and credentialing already established, an insurance-integrated or hybrid model maximizes per-visit revenue and builds on infrastructure you already carry.

If you are an employer or HR platform, the B2B benefits model offers stable contract revenue with predictable renewal cycles assuming you have the sales infrastructure and patience for enterprise procurement timelines.

If you are a wellness brand, fitness company, supplement business, or any DTC consumer brand with an existing audience and no clinical infrastructure, the white label subscription model delivers the best risk-adjusted return. You own the patient relationship. You set pricing. You earn margin on clinical program revenue. You do not hire providers, negotiate pharmacy contracts, or build HIPAA infrastructure.

The evaluation framework is straightforward: How much capital do you have before you need revenue? How long can you sustain a pre-revenue build? What clinical differentiation, if any, do you need that no existing platform provides? If the answer to that last question is "none," the platform model is almost always the right answer for brand operators in 2026.

Conclusion

The telehealth business model landscape is consolidating around operators who chose the right infrastructure architecture before they spent on patient acquisition. Compliance shortcuts, custom builds without clinical differentiation, and manual workflows that break at volume these are the structural decisions that determine which operators scale and which ones rebuild.

For non-clinical brand operators, the white label subscription model is the fastest and most capital-efficient path to a defensible telehealth revenue stream. FUSE Health provides the complete clinical infrastructure to launch that model licensed providers, pharmacy integrations, HIPAA compliance, and subscription management — in a platform that scales with your program rather than against it.

References

[1] Grand View Research, "Telemedicine Market Size & Share Report," 2024. grandviewresearch.com

[2] Hims & Hers Health, Inc., Annual Report (Form 10-K), FY 2024. SEC EDGAR, sec.gov

[3] McKinsey & Company, "Telehealth: A quarter-trillion-dollar post-COVID-19 reality?" Consumer Health Survey, 2024.

⚠ Medical & Legal DisclaimerThis article is for informational purposes only and does not constitute medical advice, legal advice, or a guarantee of clinical or financial outcomes. All telehealth programs should be developed in consultation with qualified legal and clinical professionals. Revenue projections referenced are illustrative and not guarantees of financial performance. Regulatory requirements change — verify current requirements with qualified counsel before launch.
Daniel Meursing
Daniel Meursing
CEO

Daniel is a two-time founder who has scaled service businesses across major U.S. markets. A Y Combinator competition winner, he focuses on removing operational and regulatory barriers so operators can build and scale modern healthcare businesses.

Background
Startup Operations & Service Systems
Experience
2x Founder, Multi-Market U.S. Scaling
Qualifications
Healthtech Market Expertise & Operational Scaling
Key Achievement
Scaled Premier Staff & Eventstaff across major U.S. markets

Frequently Asked Questions

What is the most profitable telehealth business model in 2026?
The DTC subscription model consistently delivers the strongest unit economics at scale. Converting episodic care needs into monthly subscriptions compounds LTV, lowers effective CAC, and produces predictable revenue. For non-clinical operators specifically, the white label platform model often delivers the fastest path to profitability because it eliminates clinical infrastructure overhead entirely you earn margin on patient fees without carrying provider payroll, credentialing costs, or malpractice insurance. Platforms like FUSE Health are built for this model, but any platform should be evaluated on LegitScript certification, pharmacy integration depth, and provider coverage breadth before commitment.
Can I start a telehealth business without a medical license?
Yes. Non-licensed operators can legally launch and operate a telehealth business by partnering with a full-stack white label platform that maintains proper clinical governance and MSO (management services organization) separation. Under this structure, licensed providers within the platform make all prescribing decisions. The operator owns the brand, sets patient pricing, and manages marketing. This structure is legally compliant when properly implemented — consult a healthcare attorney familiar with your target states before launch to verify your specific program structure.
How does a white label telehealth platform work?
A white label telehealth platform provides the entire clinical and operational infrastructure under your brand. This includes licensed provider networks credentialed across covered states, asynchronous intake and review workflows, pharmacy fulfillment integrations, HIPAA-compliant patient data management, and prescription processing. You customize the brand experience, set pricing, and manage patient acquisition. The platform handles everything clinical behind the scenes — patients interact only with your brand. Before selecting a platform, verify LegitScript certification status, specific pharmacy partner identities, and state coverage breadth.
What is the difference between DTC and B2B telehealth models?
DTC (direct-to-consumer) telehealth sells clinical services directly to individual patients via subscription or per-visit pricing. Revenue scales with patient volume and LTV, and acquisition runs through digital channels. B2B telehealth sells access to employers, insurers, or enterprise clients as bundled wellness benefits. B2B delivers more predictable contract revenue but involves longer sales cycles and institutional volume commitments. DTC is generally better suited for wellness brands and non-clinical operators with existing consumer audiences. B2B fits operators with existing enterprise relationships and the sales structure to close institutional contracts.
How long does it take to launch a telehealth business with FUSE Health?
Most operators on a full-stack white label platform launch within weeks rather than months, because the clinical infrastructure, compliance layer, and pharmacy integrations already exist. Setup time focuses on brand configuration and acquisition strategy rather than building underlying infrastructure. Custom clinic builds typically require 12 to 18 months before a first patient is seen. Any quoted launch timeline should be verified by speaking with current operators on the platform.

Building a Peptide Brand?

See how FUSE infrastructure can help you launch and scale a compliant program faster.